Sudden onset of interstitial lung disease induced by gefitinib in a lung cancer patient with multiple drug allergy

Keisuke Aoe, Akio Hiraki, Tomoyuki Murakami, Tadashi Maeda, Yoshiki Umemori, Hideki Katayama, Ryosuke Eda, Hiroyasu Takeyama

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Gefitinib is an oral selective inhibitor of the epidermal growth factor receptor tyrosine kinase which is effective for patients with advanced non-small cell lung cancer. A 75-year-old man with advanced adenocarcinoma of the lung was treated with gefitinib. He had a history of allergy to several antibiotics and Welder's lung. Two days after initiation, he developed acute interstitial lung disease (ILD) and died of respiratory failure due to progression of ILD. Critical assessment pointed to gefitinib as the likely cause of this complication. This is the first report of rapid gefitinib-induced ILD. This case should alert physicians to the potential for dangerous pulmonary side-effects of gefitinib therapy, especially in patients with drug allergy.

Original languageEnglish
Pages (from-to)415-418
Number of pages4
JournalAnticancer Research
Volume25
Issue number1 B
Publication statusPublished - Jan 2005
Externally publishedYes

Fingerprint

Drug Hypersensitivity
Interstitial Lung Diseases
Lung Neoplasms
Lung
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Respiratory Insufficiency
Protein-Tyrosine Kinases
Hypersensitivity
gefitinib
Anti-Bacterial Agents
Physicians

Keywords

  • Drug allergy
  • Gefitinib
  • Interstitial lung disease (ILD)
  • Iressa

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Aoe, K., Hiraki, A., Murakami, T., Maeda, T., Umemori, Y., Katayama, H., ... Takeyama, H. (2005). Sudden onset of interstitial lung disease induced by gefitinib in a lung cancer patient with multiple drug allergy. Anticancer Research, 25(1 B), 415-418.

Sudden onset of interstitial lung disease induced by gefitinib in a lung cancer patient with multiple drug allergy. / Aoe, Keisuke; Hiraki, Akio; Murakami, Tomoyuki; Maeda, Tadashi; Umemori, Yoshiki; Katayama, Hideki; Eda, Ryosuke; Takeyama, Hiroyasu.

In: Anticancer Research, Vol. 25, No. 1 B, 01.2005, p. 415-418.

Research output: Contribution to journalArticle

Aoe, K, Hiraki, A, Murakami, T, Maeda, T, Umemori, Y, Katayama, H, Eda, R & Takeyama, H 2005, 'Sudden onset of interstitial lung disease induced by gefitinib in a lung cancer patient with multiple drug allergy', Anticancer Research, vol. 25, no. 1 B, pp. 415-418.
Aoe, Keisuke ; Hiraki, Akio ; Murakami, Tomoyuki ; Maeda, Tadashi ; Umemori, Yoshiki ; Katayama, Hideki ; Eda, Ryosuke ; Takeyama, Hiroyasu. / Sudden onset of interstitial lung disease induced by gefitinib in a lung cancer patient with multiple drug allergy. In: Anticancer Research. 2005 ; Vol. 25, No. 1 B. pp. 415-418.
@article{67b09467399d4f46b1c2f73168109ebf,
title = "Sudden onset of interstitial lung disease induced by gefitinib in a lung cancer patient with multiple drug allergy",
abstract = "Gefitinib is an oral selective inhibitor of the epidermal growth factor receptor tyrosine kinase which is effective for patients with advanced non-small cell lung cancer. A 75-year-old man with advanced adenocarcinoma of the lung was treated with gefitinib. He had a history of allergy to several antibiotics and Welder's lung. Two days after initiation, he developed acute interstitial lung disease (ILD) and died of respiratory failure due to progression of ILD. Critical assessment pointed to gefitinib as the likely cause of this complication. This is the first report of rapid gefitinib-induced ILD. This case should alert physicians to the potential for dangerous pulmonary side-effects of gefitinib therapy, especially in patients with drug allergy.",
keywords = "Drug allergy, Gefitinib, Interstitial lung disease (ILD), Iressa",
author = "Keisuke Aoe and Akio Hiraki and Tomoyuki Murakami and Tadashi Maeda and Yoshiki Umemori and Hideki Katayama and Ryosuke Eda and Hiroyasu Takeyama",
year = "2005",
month = "1",
language = "English",
volume = "25",
pages = "415--418",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1 B",

}

TY - JOUR

T1 - Sudden onset of interstitial lung disease induced by gefitinib in a lung cancer patient with multiple drug allergy

AU - Aoe, Keisuke

AU - Hiraki, Akio

AU - Murakami, Tomoyuki

AU - Maeda, Tadashi

AU - Umemori, Yoshiki

AU - Katayama, Hideki

AU - Eda, Ryosuke

AU - Takeyama, Hiroyasu

PY - 2005/1

Y1 - 2005/1

N2 - Gefitinib is an oral selective inhibitor of the epidermal growth factor receptor tyrosine kinase which is effective for patients with advanced non-small cell lung cancer. A 75-year-old man with advanced adenocarcinoma of the lung was treated with gefitinib. He had a history of allergy to several antibiotics and Welder's lung. Two days after initiation, he developed acute interstitial lung disease (ILD) and died of respiratory failure due to progression of ILD. Critical assessment pointed to gefitinib as the likely cause of this complication. This is the first report of rapid gefitinib-induced ILD. This case should alert physicians to the potential for dangerous pulmonary side-effects of gefitinib therapy, especially in patients with drug allergy.

AB - Gefitinib is an oral selective inhibitor of the epidermal growth factor receptor tyrosine kinase which is effective for patients with advanced non-small cell lung cancer. A 75-year-old man with advanced adenocarcinoma of the lung was treated with gefitinib. He had a history of allergy to several antibiotics and Welder's lung. Two days after initiation, he developed acute interstitial lung disease (ILD) and died of respiratory failure due to progression of ILD. Critical assessment pointed to gefitinib as the likely cause of this complication. This is the first report of rapid gefitinib-induced ILD. This case should alert physicians to the potential for dangerous pulmonary side-effects of gefitinib therapy, especially in patients with drug allergy.

KW - Drug allergy

KW - Gefitinib

KW - Interstitial lung disease (ILD)

KW - Iressa

UR - http://www.scopus.com/inward/record.url?scp=16344363002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16344363002&partnerID=8YFLogxK

M3 - Article

C2 - 15816604

AN - SCOPUS:16344363002

VL - 25

SP - 415

EP - 418

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1 B

ER -